Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clearance of Escherichia coli Nissle 1917 in the gastrointestinal tract of healthy volunteers
2016-001240-19Phase 2Completed
- Sponsor
- Synlogic
- Start
- Jul 2016
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of escherichia coli nissle 1917 in autoimmune colitis and chronic constipation (2 arms), sponsored by Synlogic. Primary endpoint: Clearance of Escherichia coli Nissle 1917 at 24 weeks. Started Jul 2016; status: completed.
02
Drugs
escherichia coli nissle 1917
03
Conditions
autoimmune colitischronic constipation
Beyond the preview
Go deeper on 2016-001240-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001240-19.